Trial · NCT02709109
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | VX-371 + Hypertonic Saline | Participants With TEAEs | 65 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Hypertonic Saline | Participants With TEAEs | 66 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | VX-371 + Placebo | Participants With TEAEs | 32 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Placebo | Participants With TEAEs | 28 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | VX-371 + Hypertonic Saline | Participants With Serious TEAEs | 8 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Hypertonic Saline | Participants With Serious TEAEs | 4 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | VX-371 + Placebo | Participants With Serious TEAEs | 6 | Participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs | Placebo | Participants With Serious TEAEs | 3 | Participants | |
| Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28 | VX-371 + Hypertonic Saline | 0.1 | Standard Error 0.8 | percentage points | |
| Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28 | Hypertonic Saline | -0.1 | Standard Error 0.8 | percentage points | |
| Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28 | VX-371 + Placebo | -0.8 | Standard Error 1.1 | percentage points | |
| Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28 | Placebo | 0.8 | Standard Error 1.1 | percentage points | |
| Plasma Concentrations of VX-371 | VX-371 + Hypertonic Saline | Day 1: Pre-dose | 0.00 | Standard Deviation 0.00 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Placebo | Day 1: Pre-dose | 0.18 | Standard Deviation 1.17 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Hypertonic Saline | Day 1: Post-dose | 2.57 | Standard Deviation 2.35 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Placebo | Day 1: Post-dose | 5.64 | Standard Deviation 4.27 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Hypertonic Saline | Day 14: Pre-dose | 1.63 | Standard Deviation 3.06 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Placebo | Day 14: Pre-dose | 2.77 | Standard Deviation 4.77 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Hypertonic Saline | Day 14: Post-dose | 5.81 | Standard Deviation 5.44 | Picograms per milliliter (pg/mL) |
| Plasma Concentrations of VX-371 | VX-371 + Placebo | Day 14: Post-dose | 11.0 | Standard Deviation 9.74 | Picograms per milliliter (pg/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02709109/results